Pappas Ventures
SEC exempt reporting adviser (venture capital exemption).
- HQ
- NC
Pappas Ventures, through Pappas Capital, invests exclusively in the life science sector, including biotechnology, biopharmaceuticals, drug delivery and medical devices. Its portfolio includes Altay Therapeutics, 4DMT, Curzion Pharmaceuticals and Afferent. It also runs the Catalyst Fund, a partnership with Wake Forest University Health Sciences that funds translational life science technologies, with possible seed investments in start-ups.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Pre-seed, Seed, Growth | Not enough dated deals |
| Sectors | Biotech, Medical devices, Life sciences and research tools | Not enough dated deals |
| Regions | Global, NC | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| LeVert Ventures, LP Pappas Capital invests in life science companies, including biotechnology, biopharmaceuticals, drug delivery and medical devices. It also funds translational life science technologies, with possible seed investments in start-ups, and backs next-generation life science companies from concept to commercialization. Inferred from the firm's website | approx. 2024 | $50M (Form D) | Open, writing first checks |
| Pappas Life Science Ventures VI, LP Pappas Capital invests in life science companies, including biotechnology, biopharmaceuticals, drug delivery and medical devices. It also funds translational life science technologies, with possible seed investments in start-ups, and backs next-generation life science companies from concept to commercialization. Inferred from the firm's website | approx. 2022 | $250M (Form D) | Late investment period |
| PV VI CEO Fund, LP Pappas Capital invests in life science companies, including biotechnology, biopharmaceuticals, drug delivery and medical devices. It also funds translational life science technologies, with possible seed investments in start-ups, and backs next-generation life science companies from concept to commercialization. Inferred from the firm's website | approx. 2022 | $25M (Form D) | Late investment period |
| Asia Innovation Ventures, LP | 2021 | $200M (Form D) | Follow-ons only |
03 · People across funds
- Arthur Pappas, Managing Partner of the General Partner
PV VI CEO Fund, LP (Named on Form D); Asia Innovation Ventures, LP (Named on Form D)
- NA Arthur M. Pappas, Manager of the General Partner
Pappas Life Science Ventures VI, LP (Named on Form D)
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://www.pappas-capital.com
- https://www.pappas-capital.com/portfolio/
- https://www.pappas-capital.com/pappas-specialized-funds/
- https://www.pappas-capital.com/wake-forest-innovation-catalyst-fund/
- https://www.pappas-capital.com/for-entrepreneurs/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026